Results 21 to 30 of about 15,297 (160)

Non-linear Dose Response of Lymphocyte Cell Lines to Microtubule Inhibitors

open access: yesFrontiers in Pharmacology, 2019
Microtubule (MT) inhibitors show anti-cancer activity in a wide range of tumors in vitro and demonstrate high clinical efficacy. To date they are routinely included into many chemotherapeutic regimens.
Daria M. Potashnikova   +9 more
doaj   +1 more source

PERORAL FORMS OF CYTOSTATIC DRUGS IN THERAPY OF METASTATIC MAMMARY GLAND CANCER: ROLE IN CLINICAL PRACTICE

open access: yesМедицинский совет, 2016
Modern therapeutic approaches allow achieving stable therapeutic effect, extension and maximum long-term preservation of the quality of life of metastatic mammary gland cancer patients.
G. M. TELETAEVA   +8 more
doaj   +1 more source

Case report: Secondary sclerosing cholangitis induced by lapatinib and vinorelbine in a metastasis breast cancer patient

open access: yesThoracic Cancer, 2021
Secondary sclerosing cholangitis (SSC) is a rare cholestatic liver disease that may have a severe clinical course. A 61‐year‐old woman with a history of metastasis breast cancer was admitted to our hospital for the second cycle of chemotherapy with ...
Zhuo Zhang   +11 more
doaj   +1 more source

Chemotherapy in frail elderly patients with hormone-refractory prostate cancer: A “real world” experience

open access: yesProstate International, 2016
Background: In elderly patients affected by metastatic castration-resistant prostate cancer (mCRPC) chemotherapic treatment may be the choice if one considers not only the chronological age, but also the clinical status, the functional reserve, and the ...
Paolo Tralongo   +4 more
doaj   +1 more source

The Role of Reirradiation in Childhood Progressive Diffuse Intrinsic Pontine Glioma (DIPG): An Ongoing Challenge beyond Radiobiology

open access: yesBrain Sciences, 2023
To investigate the clinical impact of multiple courses of irradiation on pediatric patients with progressive diffuse intrinsic pontine glioma (DIPG), we conducted a retrospective case series on three children treated at our institution from 2018 to 2022.
Maria Chiara Lo Greco   +7 more
doaj   +1 more source

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer

open access: yesThoracic Cancer, 2023
Background This single‐arm prospective phase II trial was performed to assess the efficacy and safety of the dual oral metronomic vinorelbine and capecitabine (mNC) regimen in women with HER2‐negative metastatic breast cancer (MBC) in China.
Yue Chai   +10 more
doaj   +1 more source

Vinorelbine as First-Line Treatment in Stage IV Canine Primary Pulmonary Carcinoma

open access: yesVeterinary Sciences, 2023
Vinorelbine (VRL), a semi-synthetic vinca alkaloid commonly used in humans with advanced lung cancer, reaches high concentrations in the lung tissue, has proven antineoplastic activity and a low toxicity profile in dogs.
Valentina Rinaldi   +4 more
doaj   +1 more source

Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis

open access: yesFuture Science OA, 2021
A retrospective analysis of 70 patients with triple-negative or hormone-resistant advanced breast carcinoma who had not previously received chemotherapy was carried out.
Maria Rosaria Valerio   +7 more
doaj   +1 more source

Anti-tumor effects of low-dose metronomic vinorelbine in combination with alpelisib in breast cancer cells

open access: yesEXCLI Journal : Experimental and Clinical Sciences, 2023
In metastatic breast cancer (MBC), PIK3CA mutations, activating the phosphatidylinositol 3-kinase (PI3K) signaling pathway seem to be associated with chemotherapy resistance and poor outcome.
Slavomir Krajnak   +9 more
doaj   +1 more source

Survival by Race and Ethnicity in Children and Adolescents/Young Adults With Relapsed/Refractory Hodgkin Lymphoma: A Pooled Analysis of Children's Oncology Group Trials

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Despite 5‐year survival rates of over 90% among children and adolescents/young adults (CAYAs) with classic Hodgkin lymphoma (cHL), 15%–20% relapse after frontline therapy. Prior analysis of frontline Children's Oncology Group (COG) clinical trials demonstrated that, despite similar rates of relapse, non‐Hispanic Black (NHB) and ...
Mallorie B. Heneghan   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy